ClinicalTrials.gg
Not yet recruitingNCT07303231Updated Dec 24, 2025

The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy

A Phase 3 interventional study of Minimally invasive surgery for esophageal cancer using near-infrared indocyanine green fluorescence to visualize the sentinel lymph node in Esophageal Cancer, Sentinel Lymph Node and Lymphadenectomy, sponsored by Fujian Medical University Union Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Fujian Medical University Union Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 502 studies in Esophageal Neoplasms with a site in China — 211 open to participants now, 238 under way, 28 of them phase 3. Esophageal Neoplasms · China.

Planned enrollment
139th of 394
144 · median 80
Started
2026
with 30 others
Phase 3
62 of 502
20 open now
Primary completion
2027-08
later than 174 of 237 live
Registered
413th of 502
by date

Among the 502 studies in Esophageal Neoplasms with a site in China, this one is the 139th largest by planned enrollment of the 394 interventional ones that give a count, is one of 31 that started in 2026, is one of 62 in phase 3, reaches primary completion later than 174 of the 237 other live ones, and was the 413th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

211 of the 502 studies in Esophageal Neoplasms with a site in China are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 502 studies in Esophageal Neoplasms with a site in China, or all of them as a file.
02

Study summary

Sentinel lymph nodes, as the primary site of tumor metastasis, play a pivotal role in assessing patient prognosis and planning subsequent treatment strategies. The investigators plan to conduct a multicenter, prospective cohort study to evaluate the effectiveness of indocyanine green (ICG)-guided near-infrared imaging in tracing sentinel lymph node during esophageal squamous cell carcinoma (ESCC) surgery, compared with the gold standard of complete lymph node dissection (CLND), in detecting metastatic disease. This study aims to address the following core questions:

  1. In ESCC patients undergoing surgery, can sentinel lymph node biopsy reduce unnecessary lymph node dissection?
  2. In ESCC patients undergoing surgery, can reducing lymph node dissection decrease postoperative complications such as chylothorax and weakened immunity? During the study, ICG will be injected around the tumor under intraoperative gastroscopy guidance, followed by tracking of fluorescent lymph nodes using a thoracoscopic near-infrared camera. Professional thoracic surgeons will group and mark these lymph nodes for intraoperative frozen pathology. Subsequent CLND and routine postoperative pathology will be performed. This study will collect patients' clinical information, ICG imaging results, pathological examination results, and other data for statistical analysis to assess the sensitivity and negative predictive value (NPV) of the ICG imaging system. If the study results support the effectiveness of the ICG imaging system, it has the potential to become an important tool for sentinel lymph node localization and biopsy in future ESCC surgeries, helping to reduce unnecessary lymph node resection and improve surgical efficiency and safety.

Participants will:

  1. Undergo minimally invasive ESCC surgery within 2 weeks of enrollment, including the 14th day.
  2. Receive ICG injection around the tumor under intraoperative gastroscopy guidance during surgery.
  3. Have perioperative, postoperative pathology, and complication information recorded.
  4. Undergo standardized follow-up after surgery.
Read the detailed description

This study will be accepted in esophageal cancer patients with Radical Esophag-ectomy as the research object. The investigators will divide participants into two groups: experimental group for injection of indocyanine green group and control group for injectable in-docyanine green group.The investigators will compare with the accuracy,false positive rate and false negative rate,sensitivity, specificity and related indicators of intraoperative lymph node cleaning,in order to explore the common position of esophageal cancer sentinel lymph node,guidance of esophageal cancer lymph node cleaning thoroughly.

03

Conditions studied

  • Esophageal Cancer
  • Sentinel Lymph Node
  • Lymphadenectomy
  • Indocyanine Green
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age and gender: 18-75 years old, male and female unlimited;
  2. Preoperative was diagnosed as esophageal squamous cell carcinoma;
  3. Preoperative combination with chemoradiotherapy;
  4. Surgical resection of esophageal carcinoma under endoscopic selection and intraoperative anastomosis;
  5. Heart, lung, liver and kidney functions can tolerate operation;
  6. Patients and their family members can understand and are willing to participate in this clinical study and sign the .

Exclusion criteria

Exclusion Criteria:

  1. Allergic to ICG or iodine;
  2. Patients with a history of chest surgery or thoracic lymph node dissection;
  3. Patients needing emergency surgery;
  4. Patients whose tumors involve neighboring organs and need to be removed by combining organs;
  5. Patients with tumor recurrence or distant ;
  6. Patients who had participated in or were participating in other clinical trials within the previous 4 weeks were included;
  7. A history of serious mental illness;
  8. Pregnant or lactating women;
  9. Patients with other conditions considered by the researcher should not participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    (ICG group) receiving VATS with near-infrared imaging with indocyanine green to visualize

    Drug: Minimally invasive surgery for esophageal cancer using near-infrared indocyanine green fluorescence to visualize the sentinel lymph node

  • No intervention
    (Control group) receiving VATS without near-infrared imaging with indocyanine g

Interventions

  • DrugMinimally invasive surgery for esophageal cancer using near-infrared indocyanine green fluorescence to visualize the sentinel lymph node

    A multicenter, prospective cohort study will be conducted. Enrolled patients with esophageal squamous cell carcinoma will undergo minimally invasive radical esophagectomy. During surgery, ICG will be injected around the tumor under gastroscopy guidance, and fluorescent lymph nodes will be tracked using a thoracoscopic near-infrared camera. These lymph nodes will be grouped and marked by professional thoracic surgeons, and intraoperative frozen pathology results will be recorded. Subsequent CLND will be performed. The study will collect and analyze patients' clinical information, ICG imaging results, and pathological examination results to explore the effectiveness of the ICG imaging system.

06

What researchers measure

Primary outcomes

  1. Accuracy rate of lymph node dissection

    According to postoperative pathological results, investigate the detection rate of metastatic lymph nodes using the near-infrared indocyanine green fluorescence imaging system in lymph node dissection for esophageal squamous cell carcinoma

    Time frame: 1 week after operation

Secondary outcomes

  1. Sensitivity and specificity of lymph node dissection

    Sensitivity and specificity of lymph node dissection of each arm(according to postoperative pathology)

    Time frame: 1 week after operation

  2. The number of lymph nodes

    The number of lymph nodes between the both groups

    Time frame: 1 week after operation

  3. False positive rate of lymph node dissection

    False positive rate of lymph node dissectionof each arm(according to postoperative pathology)

    Time frame: 1 week after operation

  4. False negative rate of lymph node dissection

    False negative rate of lymph node dissection of each arm(according to postoperative pathology)

    Time frame: 1 week after operation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Aug 2027, 19 months later.

Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2025
First posted
Dec 24, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Feb 1, 2028
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07303231
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Dec 24, 2025

Study contacts

Bin Zheng, M.D.
Contact
lacustrian@163.com
15959002753
Jianting Du, M.D., Ph.D
Contact
dujt1220@fjmu.edu.cn
13023806690

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion